New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated t...
Saved in:
Main Author: | Sung-Won Jang (Author) |
---|---|
Format: | Book |
Published: |
Yong Chan Lee,
2016-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hepatotoxicity of new oral anticoagulants: literature review
by: N. S. Popova, et al.
Published: (2019) -
Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy
by: Ylenia Ingrasciotta, et al.
Published: (2021) -
FEATURES OF EDUCATIONAL AND METHODICAL WORK AT PIVOTAL TECHNICAL UNIVERSITY
by: Olga A. Sotnikova, et al.
Published: (2016) -
Hepatotoxicity of New Oral Anticoagulants
by: A. R. Kasimova, et al.
Published: (2018) -
Direct oral anticoagulants: A new chapter in anticoagulation therapy
by: Stepanović-Petrović Radica, et al.
Published: (2020)